SPECIAL REPORT: The Launches of Opsumit, Adempas, and Orenitram into the Pulmonary Arterial Hypertension Market
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are increasingly required in order to alleviate patient symptoms and increase both quality and duration of life.
Related Market Assessment Reports
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
